Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Generalized Anxiety Disorder (GAD)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Generalized Anxiety Disorder (GAD). Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-005674-47 Sponsor Protocol Number: CL3-20098-050 Start Date*: 2007-10-26
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ...
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    10.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SE (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002577-23 Sponsor Protocol Number: CL2-20098-040 Start Date*: 2004-12-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose doub...
    Medical condition: Generalised Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10018075 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-001666-15 Sponsor Protocol Number: CL3-20098-087 Start Date*: 2013-06-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo given orally for 12 weeks in non depressed out-patients with Generalized Anxiety Disorder. A 12-week randomise...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003181-41 Sponsor Protocol Number: EFC5893 Start Date*: 2005-08-16
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350...
    Medical condition: Generalized Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010902-13 Sponsor Protocol Number: F1J-MC-HMGF(a) Start Date*: 2010-08-03
    Sponsor Name:LILLY S.A.
    Full Title: Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizada Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anx...
    Medical condition: Trastorno de ansiedad generalizada Generalized anxiety disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    11 10018105 Trastorno de ansiedad generalizada LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003421-17 Sponsor Protocol Number: CL3-20098-051 Start Date*: 2009-02-18
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003180-23 Sponsor Protocol Number: EFC5891 Start Date*: 2006-02-02
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 m...
    Medical condition: Generalized Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-001673-15 Sponsor Protocol Number: 12473A Start Date*: 2008-09-18
    Sponsor Name:H. Lundbeck A/S
    Full Title: A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)
    Medical condition: Generalised Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017571 GAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000761-32 Sponsor Protocol Number: A5361018 Start Date*: 2008-09-05
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G...
    Medical condition: Generalized Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001779-35 Sponsor Protocol Number: 4 Start Date*: 2013-02-15
    Sponsor Name:University of Southampton
    Full Title: The effects of pregabalin augmentation of antidepressant drug on neuro-cognitive functioning in patients with generalized anxiety disorder
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004443-11 Sponsor Protocol Number: A5361022 Start Date*: 2009-02-04
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A 52-WEEK OPEN-LABEL SAFETY STUDY OF PD 0332334 IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000521-61 Sponsor Protocol Number: 750201.01.016 Start Date*: 2007-03-12
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, double-blind, randomized, reference-controlled study to prove the efficacy, safety and tolerability of Lavender oil WS 1265 (Lavandula angustifolia) in patients with generalized anxie...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003643-23 Sponsor Protocol Number: CRO-06-76 - AB/GAD/21 Start Date*: 2006-06-14
    Sponsor Name:Abiogen Pharma S.p.A.
    Full Title: Efficacy and tolerability study of a novel CNS drug ABIO 08/01 administered for 8 weeks to patients with generalised anxiety disorders
    Medical condition: generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017571 GAD LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004768-32 Sponsor Protocol Number: A0081147 Start Date*: 2008-04-21
    Sponsor Name:Pfizer S.A.
    Full Title: “ESTUDIO DE SEGURIDAD Y EFICACIA A LARGO PLAZO DE PREGABALINA EN SUJETOS CON TRASTORNO DE ANSIEDAD GENERALIZADA” "LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANX...
    Medical condition: Trastorno de ansiedad generalizada (TAG)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) LT (Completed) FI (Completed) AT (Completed) CZ (Completed) SI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-005597-67 Sponsor Protocol Number: EFC4846 Start Date*: 2006-03-29
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in elderly patients with Major Depressive Di...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004077-16 Sponsor Protocol Number: 14/0249 Start Date*: 2014-12-03
    Sponsor Name:University College London Joint Research Office
    Full Title: A Phase IV randomised controlled trial of the selective serotonin reuptake inhibitor Sertraline versus Cognitive Behavioural Therapy for anxiety symptoms in people with Generalised Anxiety Disorder...
    Medical condition: Generalised anxiety disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10018075 Generalised anxiety disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000763-42 Sponsor Protocol Number: A5361020 Start Date*: 2008-09-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G...
    Medical condition: Generalized Anxiety Disorder (GAD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000762-23 Sponsor Protocol Number: A5361019 Start Date*: 2008-09-11
    Sponsor Name:PFIZER
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK, PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT ...
    Medical condition: Generalized Anxiety Disorder (GAD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002855 Anxiety LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003042-47 Sponsor Protocol Number: InsulaTOP Start Date*: 2015-12-16
    Sponsor Name:Centre Hospitalier Henri Laborit
    Full Title: Psycho-biological substrates of therapeutic benefit of thermal cure on Generalized Anxiety Disorders
    Medical condition: Generalised Anxiety Disorders
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001500-13 Sponsor Protocol Number: A0081012 Start Date*: 2005-01-24
    Sponsor Name:Pfizer Ltd.
    Full Title: An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 07:08:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA